Predictive markers for response to interferon therapy in patients with multiple sclerosis

Area of Science:

• Immunology
• Neuroscience
• Biomarker Discovery

Background:

• Prolonged interferon beta (IFN beta) therapy can lead to anti-IFN beta antibodies (BAbs), with a subset of neutralizing antibodies (NAbs) reducing treatment efficacy.
• Myxovirus-resistance-protein A (MxA) serves as a reliable biomarker for IFN beta bioactivity.
• Assessing the prognostic value of MxA mRNA, NAbs, and BAbs is crucial for predicting relapse risk in IFN beta-treated patients.

Purpose of the Study:

• To evaluate the prognostic value of MxA mRNA, NAbs, and BAbs in predicting new relapses in patients undergoing IFN beta therapy.
• To determine the clinical significance of these biomarkers in relation to relapse-free survival (RFS).

Main Methods:

• A 3-year prospective study involving 137 patients treated with IFN beta.
• Blood samples collected at 12 ± 3 months for MxA mRNA, NAbs, and BAbs analysis.
• Relapse-free survival (RFS) analysis using predefined thresholds for biomarker positivity/negativity.

Main Results:

• MxA-negative patients exhibited significantly poorer RFS rates compared to MxA-positive patients (p < 0.0001, HR = 2.87).
• NAb-positive patients also showed poorer RFS rates than NAb-negative patients (p = 0.0013, HR = 2.49).
• BAbs did not demonstrate clear clinical significance in predicting relapse risk.

Conclusions:

• Both MxA mRNA and NAbs are significant predictors of new relapse risk in IFN beta-treated patients.
• MxA mRNA is recommended as the preferred biomarker for monitoring IFN beta therapy due to its slightly stronger prognostic value and simpler measurement.
• These findings can aid in tailoring IFN beta treatment strategies for individual patients with multiple sclerosis (MS).